Filing Details

Accession Number:
0000874015-15-000033
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-02-17 17:39:14
Reporting Period:
2015-02-12
Filing Date:
2015-02-17
Accepted Time:
2015-02-17 17:39:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874015 Isis Pharmaceuticals Inc ISIS Pharmaceutical Preparations (2834) 330336973
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1073384 H Joseph Wender C/O Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad CA 92010
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-02-12 10,000 $3.95 47,217 No 4 M Indirect By Trust
Common Stock Disposition 2015-02-12 10,000 $62.15 37,217 No 4 S Indirect By Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Indirect By Trust
No 4 S Indirect By Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Employee Director Stock Option (right to buy) Disposition 2015-02-12 10,000 $0.00 10,000 $3.95
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2009-07-01 2015-06-30 No 4 M Indirect
Footnotes
  1. Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2015.
  2. The sale was a result of shares owned. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.960 to $62.325, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.